CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
Aripiprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00177008
NCT00177008Phase 4Completed
CompareCT.gov

Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

University of Medicine and Dentistry of New Jersey·interventional·Posted Sep 15, 2005·Updated Jan 29, 2007

In Brief

A Phase 4 clinical trial evaluating Aripiprazole for Schizophrenia and 2 related conditions. Completed, across 1 site.

Detailed Summary

This study will determine the efficacy of a medication switch to Aripiprazole for the treatment of schizophrenia or schizoaffective disorder in patients with moderate to high symptoms of social anxiety. Specifically the study will test the possibility that a medication switch to Aripiprazole reduces symptoms of social anxiety in this patient population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder, Social Anxiety Disorder
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 15, 2005
Enrollment StartMar 1, 2004
Study CompletionJan 1, 2007
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

Aripiprazoledrug